Table 3.
Demographics of the subjects in GERA and MGB Biobank analysed for the asthma-related exacerbation outcome
| GERA (n=4541) |
MGB biobank (n=505) |
|||||
|---|---|---|---|---|---|---|
| Cases (n=646) | Controls (n=3895) | P value | Cases (n=202) | Controls (n=303) | P value | |
| Age (years, mean±SD) | 62.6 (±14.2) | 62.8 (±14.5) | 0.5 | 59.4 (±16.0) | 56.9 (±16.6) | 0.1 |
|
| ||||||
| Female sex | 502 (77.7%) | 2686 (69.0%) | <0.001 | 130 (64.4%) | 194 (64.0%) | 0.94 |
|
| ||||||
| Smoking status | 0.58 | 0.23 | ||||
|
| ||||||
| Never | 387 (61.6%) | 2282 (60.5%) | 61 (60.4%) | 92 (52.9%) | ||
|
| ||||||
| Current or former | 241 (38.4%) | 1492 (39.5%) | 40 (39.6%) | 82 (47.1%) | ||
|
| ||||||
| BMI (kg/m2, mean±SD) | 29.6 (±6.2) | 28.7 (±6.0) | <0.001 | 31.2 (±8.9) | 28.4 (±6.9) | 0.01 |
|
| ||||||
| Co-morbidities | ||||||
|
| ||||||
| Allergic rhinitis | 300 (46.4%) | 1659 (42.6%) | 0.07 | 137 (67.8%) | 164 (54.1%) | 0.002 |
|
| ||||||
| GERD | 216 (33.4%) | 1053 (27.0%) | <0.001 | 133 (65.8%) | 170 (56.1%) | 0.03 |
|
| ||||||
| Concurrent asthma medications* | ||||||
|
| ||||||
| Long-acting β-agonists | 55 (8.5%) | 187 (4.8%) | <0.001 | 116 (57.4%) | 137 (45.2%) | 0.01 |
|
| ||||||
| Antileukotrienes | 31 (4.8%) | 101 (2.6%) | <0.05 | 66 (32.7%) | 84 (27.7%) | 0.23 |
|
| ||||||
| Anticholinergics | 14 (2.2%) | 61 (1.6%) | 0.27 | 55 (27.2%) | 41 (13.5%) | <0.001 |
|
| ||||||
| Biologics* | – | – | – | 8 (4.0%) | 3 (1.0%) | 0.03 |
*
In MGB Biobank, omalizumab and mepolizumab only.
BMI, body mass index; GERA, Genetic Epidemiology Research on Adult and Aging; MGB, Mass General Brigham.